Trustees also approved multiple development and infrastructure projects.

GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Building up its base of medicines for lung diseases, GSK said ...

GSK has doubled down on its belief in the silent interfering RNA (siRNA) modality by inking a licensing agreement worth up to just over $1bn with Chinese company, Frontier Biotechnologies. Through ...

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas GSK is the largest ...

(RTTNews) - British drug major GSK plc (GSK, GSK.L) reported Wednesday higher profit and revenues in its fourth quarter, and issued fiscal 2026 outlook, expecting increase in core profit and turnover.

GSK has surged ~46% YTD, far outpacing both the healthcare sector and S&P 500, which is notable considering the spectre of high US tariffs hanging over it. The recent US-UK pharmaceuticals deal, the ...

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster. The US Food and Drug Administration approved Exdensur as an add-on maintenance ...

Drugmaker GSK and U.S. biotechnology company AnaptysBio started litigation against one another, with each saying the other party breached a licensing agreement for cancer treatment Jemperli. Tesaro, a ...

GSK Plc raised its profit and sales forecasts for the year, aided by its HIV and immunology medicines, in Emma Walmsley’s last report as chief executive officer. The British drugmaker expects earnings ...

GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday, tasking the new leader to deliver shareholder value and prepare for the ...

GSK plc announced Wednesday that it will invest roughly $1.2B to build a new facility for pharmaceutical manufacturing and research and development in Upper Merion, Pennsylvania, as well as to upgrade ...